13F Holdings
中文EN

IOVA IOVANCE BIOTHERAPEUTICS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1425205 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY51.3%
TTM net income YoY44.5%
TTM EPS YoY58.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin53.2%
Operating margin-60.8%
Net margin-58.2%
FCF margin-57.0%
EBITDA margin-54.0%

Returns

ROE-29.1%
ROA-23.3%
ROIC (approx.)-28.0%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets18.0%
Debt / equity0.00x
Current ratio5.20x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue6.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$263.50M$164.07M$1.19M——
Cost of revenue$173.18M$93.25M$1.03M——
Gross profit$90.32M$70.82M$156,000——
R&D expense$300.27M$276.23M$333.19M$294.78M$259.04M
SG&A expense$152.32M$152.27M$106.10M$104.10M$83.66M
Operating income-$403.36M-$395.28M-$460.56M-$398.88M-$342.70M
Pretax income-$393.05M-$375.00M-$447.52M-$395.89M-$342.25M
Income tax-$2.07M-$2.83M-$3.48M$0$0
Net income-$390.98M-$372.18M-$444.04M-$395.89M-$342.25M
EBITDA-$390.49M-$384.02M-$448.99M-$389.57M-$339.59M
EPS (basic)-1.09-1.28-1.89-2.49-2.23
EPS (diluted)-1.09-1.28-1.89-2.49-2.23
Weighted avg. shares (diluted)357,345289,877235,131159,259153,406
Balance sheet
Cash & equivalents$163.08M$122.05M$114.89M$238.16M$84.31M
Short-term investments$133.90M$208.09M$164.98M$240.11M$426.18M
Receivables$82.45M$69.34M$151,000——
Inventory$51.68M$51.52M$10.37M——
Current assets$442.69M$457.02M$307.85M$479.12M$507.96M
PP&E, net$131.11M$109.08M$114.03M$105.23M$100.94M
Intangibles$279.32M$282.40M$229.26M——
Total assets$913.17M$910.43M$780.35M$663.98M$777.33M
Current liabilities$138.36M$122.34M$110.31M$91.48M$89.20M
Total liabilities$214.59M$200.02M$195.74M$164.34M$155.67M
Shareholders' equity$698.58M$710.40M$584.61M$499.64M$621.66M
Shares outstanding411.94M305.25M256.14M187.81M157.00M
Cash flow statement
Operating cash flow-$302.41M-$352.98M-$361.82M-$292.76M-$227.94M
Capital expenditure$33.84M$11.07M$22.29M$20.43M$37.57M
Free cash flow-$336.24M-$364.05M-$384.11M-$313.18M-$265.51M
Investing cash flow$47.50M-$96.41M-$155.24M$256.45M$132,000
Financing cash flow$300.77M$390.66M$462.96M$190.15M$239.27M
Depreciation & amortization$12.86M$11.26M$11.57M$9.31M$3.11M
Stock-based compensation$61.58M$109.63M$62.62M$84.02M$69.77M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.